PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 18, 2026Journal of Surgical Case Reports0 citationsOpen Access

Conservative management of a delayed enterocutaneous fistula following emergency distal gastrectomy using sequential somatostatin analogues

View Full Paper
AZAlexandra ZalumsAHAngus Hibberd

Key Points

  • To evaluate the effectiveness of sequential somatostatin analogues in managing a delayed enterocutaneous fistula after distal gastrectomy.
  • Reported a case of delayed enterocutaneous fistula following distal gastrectomy.
  • Managed the fistula non-operatively with octreotide followed by lanreotide.
  • Monitored fistula output and outpatient care during treatment.
  • Octreotide reduced fistula output significantly.
  • Transition to monthly lanreotide facilitated outpatient management.
  • The fistula eventually closed without the need for surgical intervention.

Abstract

Abstract Enterocutaneous fistulas (ECFs) are serious postoperative complications associated with significant morbidity and mortality. Somatostatin analogues are widely used to reduce fistula output, although their effect on definitive closure remains uncertain. Evidence regarding long-acting formulations in postoperative ECFs is limited, particularly in the context of outpatient management. We report a case of delayed postoperative ECF following emergency distal gastrectomy for perforated gastric ulcer. The patient was managed non-operatively using sequential administration of short-acting Octreotide followed by long-acting Lanreotide. Conservative management avoided reoperation despite recurrent collections and prolonged fistula activity. Octreotide therapy was associated with reduction in fistula output, and transition to monthly Lanreotide enabled simplified outpatient care. The fistula subsequently closed without surgical re-intervention; however, spontaneous closure cannot be excluded as a contributing factor. This case emphasizes surgical decision-making in a hostile postoperative abdomen and the sequential use of somatostatin analogues in conservative community-based care.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zalums et al. (2026) studied this question.

synapsesocial.com/papers/69ba430d4e9516ffd37a3d6chttps://doi.org/10.1093/jscr/rjag176
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical trial: The effectiveness of long‐acting somatostatin analogue for output reduction of high‐output intestinal fistula or small bowel enterostomy. A randomised controlled trial2024 · 7 citations
  2. 2Thirty-day outcomes in the operative management of intestinal-cutaneous fistulas: A NSQIP analysis2020 · 12 citations
  3. 3Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas2004 · 55 citations
  4. 4A Life‐saving but Inadequately Discussed Procedure: Tube Duodenostomy. Known and Unknown Aspects2007 · 47 citations
  5. 5Somatostatin Analogues for the Treatment of Enterocutaneous Fistulas: A Systematic Review and Meta‐analysis2012 · 40 citations